Jennifer Marks

Dr. Jennifer Marks is a thoracic medical oncologist and clinical investigator at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School. She is an emerging leader in precision oncology with a strong focus on lung cancer and thymic epithelial tumors. Her work integrates translational research, biomarker discovery, and clinical trial development to advance targeted therapies and improve outcomes for patients with thoracic malignancies. Dr. Marks has led innovative investigator-initiated trials and contributes extensively to multidisciplinary oncology programs, with a growing international presence in thoracic oncology research and education.

Current Position

• Thoracic Medical Oncologist, Dana-Farber Cancer Institute
• Affiliate Staff, Medical Oncology, Brigham and Women’s Hospital
• Instructor in Medicine, Harvard Medical School

Education & Training

• MD, Tulane University School of Medicine
• Bachelor of Fine Arts (Summa Cum Laude), Tulane University
• Residency, Internal Medicine, Emory University School of Medicine
• Fellowship, Hematology/Medical Oncology, Georgetown University
• Chief Fellow, Hematology/Medical Oncology, Georgetown University

Areas of Specialization

• Thoracic oncology
• Non-small cell lung cancer (NSCLC) and small cell lung cancer
• Thymic epithelial tumors (TETs)
• Precision oncology and biomarker-driven therapies
• Targeted therapy and immunotherapy in lung cancer
• Translational oncology and clinical trial development
• Molecular profiling and resistance mechanisms in cancer
• Early detection and cancer interception strategies

Clinical & Research Focus

• Development of targeted therapies and antibody-drug conjugates in thoracic malignancies
• Biomarker discovery and genomic profiling in lung cancer
• Investigation of MET exon 14 skipping mutations and HER2 alterations in NSCLC
• Translational research in thymic epithelial tumors and rare thoracic cancers
• Precision medicine approaches integrating molecular diagnostics and therapeutic selection
• Clinical trial design and leadership in early-phase and investigator-initiated studies
• Evaluation of resistance mechanisms and tumor evolution in lung cancer

Academic Profile

• Author of multiple peer-reviewed publications in leading journals including JAMA Oncology, Journal of Clinical Oncology, and Lung Cancer
• Contributor to research on molecular profiling, targeted therapies, and immunotherapy in thoracic malignancies
• Active peer reviewer for journals such as JAMA Oncology, Clinical Lung Cancer, and Cancer Immunology Research
• ORCID-recognized researcher with a growing international academic presence
• Contributor to educational content including podcasts, international presentations, and oncology-focused media

Clinical Trials & Research Leadership

• Principal Investigator for multiple translational and clinical research projects in thoracic oncology
• Lead developer of a Phase II clinical trial evaluating sacituzumab govitecan in thymic epithelial tumors
• Principal Investigator for STK-012 with pembrolizumab in solid tumors
• Investigator in engineered T-cell receptor (TCR) therapy trials targeting KRAS G12D mutations
• Leader in translational studies exploring MTAP deficiency and apoptosis pathways in thymic tumors
• Developer of patient-derived tumor models and functional precision oncology strategies

Leadership & Professional Roles

• Member, American Society of Clinical Oncology (ASCO)
• Member, American Society of Hematology (ASH)
• Member, International Association for the Study of Lung Cancer (IASLC)
• Member, American Association for Cancer Research (AACR)
• Member, Alliance for Clinical Trials in Oncology
• Member, ASCO Trainee and Early Career Advisory Group (TECAG)
• Contributor to ASCO clinical practice and innovation initiatives
• Participant in precision oncology alliances and collaborative research networks

Awards & Honors

• Early Career Education Award, World Conference on Lung Cancer
• Conquer Cancer / Maryland-D.C. Society of Clinical Oncology Merit Award
• FDA–AACR Oncology Educational Fellowship
• Excellence in Oncology Leadership Award, Dana-Farber Cancer Institute
• Poster competition finalist and travel award recipient at major oncology conferences
• Multiple academic scholarships and honors during medical education

Research & Scientific Contributions

• Published key studies on MET exon 14 skipping mutations and molecular subtypes of NSCLC
• Advanced understanding of targeted therapy response and resistance in lung cancer
• Contributions to research on SEZ6 expression and lineage plasticity in neuroendocrine tumors
• Investigated HER2 alterations and genomic drivers in thoracic malignancies
• Developed innovative approaches integrating functional assays and molecular profiling
• Active contributor to international oncology conferences including ASCO and IASLC

Teaching & Mentorship

• Instructor and faculty educator in thoracic oncology at Harvard Medical School
• Mentor to hematology-oncology fellows and internal medicine residents
• Active participant in tumor boards, case conferences, and multidisciplinary teaching programs
• Contributor to national and international oncology education initiatives
• Invited speaker at regional, national, and international oncology meetings

Global & Academic Engagement

• Invited speaker at international oncology conferences including IASLC and World Conference on Lung Cancer
• Contributor to global oncology discussions on precision medicine and targeted therapies
• Active engagement in oncology education through podcasts, webinars, and digital platforms
• Collaborator in international research networks focusing on lung cancer and rare tumors
• Advocate for innovation in early detection and personalized cancer care